These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23625584)

  • 1. An efficient analysis of covariance model for crossover thorough QT studies with period-specific baseline days.
    Lu K
    Pharm Stat; 2013; 12(4):192-200. PubMed ID: 23625584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficient and robust analysis of covariance model for baseline adjustment in parallel-group thorough QT/QTc studies.
    Lu K
    Stat Med; 2013 Jun; 32(14):2406-18. PubMed ID: 22996035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient analysis of covariance model for crossover thorough QT studies with period-specific pre-dose baselines.
    Lu K
    Pharm Stat; 2014; 13(6):388-96. PubMed ID: 25283768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
    Meng Z; Quan H; Fan L; Kringle R; Sun G
    J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interdependence of baseline correction method and covariance structure for crossover TQT studies.
    Li W; Maes A; Quinlan M; Anand S
    J Biopharm Stat; 2013; 23(1):82-97. PubMed ID: 23331223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed models for data from thorough QT studies: part 2. One-step assessment of conditional QT prolongation.
    Schall R
    Pharm Stat; 2011; 10(4):293-301. PubMed ID: 21061415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of statistical models adjusting for baseline in the analysis of parallel-group thorough QT/QTc studies.
    Sun GG; Quan H; Kringle R; Meng Z
    J Biopharm Stat; 2012; 22(3):438-62. PubMed ID: 22416834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
    Stylianou A; Roger J; Stephens K
    J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Handling of baseline measurements in the analysis of crossover trials.
    Chen X; Meng Z; Zhang J
    Stat Med; 2012 Jul; 31(17):1791-803. PubMed ID: 22715129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
    Sethuraman V; Sun Q
    Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recommended analysis for 2 × 2 crossover trials with baseline measurements.
    Mehrotra DV
    Pharm Stat; 2014; 13(6):376-87. PubMed ID: 25230245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.
    Meng Z; Kringle R; Chen X; Zhao PL
    J Biopharm Stat; 2010 May; 20(3):563-77. PubMed ID: 20358436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of baseline covariates on the efficiency of statistical analyses of crossover designs.
    Yan Z
    Stat Med; 2013 Mar; 32(6):956-63. PubMed ID: 22903413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.
    Schall R; Ring A
    Pharm Stat; 2011; 10(3):265-76. PubMed ID: 21574242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size calculations in thorough QT studies.
    Zhang L; Dmitrienko A; Luta G
    J Biopharm Stat; 2008; 18(3):468-82. PubMed ID: 18470756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies.
    Fosser C; Duczynski G; Agin M; Wicker P; Darpo B
    Clin Pharmacol Ther; 2009 Nov; 86(5):503-6. PubMed ID: 19339965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.